- China's National Medical Products Administration has approved AstraZeneca's (AZN -0.3%) Imfinzi (durvalumab) as a first-0line treatment for extensive-stage small cell lung cancer.
- The approval was based on data from the phase 3 CASPIAN trial that showed Imfinzi plus chemotherapy bested chemotherapy alone in terms of overall survival.
- Only ~3% of extensive-stage small cell lung cancer patients are alive five years after diagnosis.
China approves AstraZeneca's Imfinzi for small cell lung cancer
Recommended For You
More Trending News
About AZN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AZN | - | - |
AstraZeneca PLC |